MedPath

Safety and efficacy of nab-paclitaxel plus gemcitabine in the patients with recurrent pancreatic cancer after pancreatectomy

Not Applicable
Recruiting
Conditions
pancreatic cancer
Registration Number
JPRN-UMIN000031203
Lead Sponsor
niversity of Yamanashi
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
30
Inclusion Criteria

Not provided

Exclusion Criteria

1)Patients with allergy for nab-paclitaxel and gemcitabine 2) Patients with severe infection 3) Patients who are considered to be inappropriate for this study

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath